Sandro Pignata
Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
Gargiulo P, Pignata S, Berardi S, Glimelius B, Scheithauer W, Ruhstaller T, Bodoky G, Herrmann R, Dietrich D, Brauchli P. Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores. Ther Adv Med Oncol 2019; 11:1758835918818351.
02.01.2019Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores
02.01.2019Ther Adv Med Oncol 2019; 11:1758835918818351
Gargiulo Piera, Pignata Sandro, Berardi Simona, Glimelius Bengt, Scheithauer Werner, Ruhstaller Thomas, Bodoky György, Herrmann Richard, Dietrich Daniel, Brauchli Peter
Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
Gordon J, Cox M, De Placido P, Ribera D, Omlin A, Buonocore G, Chi K, Kollmannsberger C, Khalaf D, Facchini G, Sonpavde G, De Placido S, Eigl B, Cherhroudi C, Pignata S, Battaglia M, Buonerba C, Pond G, Crona D, Gillessen Sommer S, Lucarelli G, Rossetti S, Dorff T, Artale S, Locke J, Bosso D, Milowsky M, Witek M, Di Lorenzo G. Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. Oncotarget 2018; 9:19861-19873.
13.04.2018Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study
13.04.2018Oncotarget 2018; 9:19861-19873
Gordon Jacob A, Cox Michael E, De Placido Pietro, Ribera Dario, Omlin Aurelius, Buonocore Gaetano, Chi Kim, Kollmannsberger Christian, Khalaf Daniel, Facchini Gaetano, Sonpavde Guru, De Placido Sabino, Eigl Bernhard J, Cherhroudi Cyrus, Pignata Sandro, Battaglia Michele, Buonerba Carlo, Pond Gregory, Crona Daniel, Gillessen Sommer Silke, Lucarelli Giuseppe, Rossetti Sabrina, Dorff Tanya, Artale Salvatore, Locke Jennifer A, Bosso Davide, Milowsky Matthew Ivan, Witek Mira Sofie, Di Lorenzo Giuseppe